Description: Enfluvir 75mg capsules are indicated for the treatment and post-exposure prophylaxis of influenza in adults. Treatment is effective when initiated within two days of symptom onset. Post-exposure prophylaxis is recommended following contact with a clinically diagnosed influenza case during community outbreaks. Seasonal prophylaxis may be considered in exceptional circumstances (e.g., vaccine mismatch, pandemic) for individuals aged one year and older. Enfluvir is not a substitute for influenza vaccination. Use should be guided by official recommendations considering circulating virus characteristics, antiviral susceptibility, regional impact, and patient demographics.
US: temporary delays — postal services aligning new import rules, 
EU: 1–2 weeks, 🌍 Worldwide: 1–4 weeks ✈️